Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, Brodersen LE, Pardo L, Leonti A, Smith JL, Hylkema TA, Woods WG, Cooper TM, Kolb EA, Gamis AS, Aplenc R, Alonzo TA, Meshinchi S. Tarlock K, et al. Among authors: wang yc. Blood. 2021 Sep 30;138(13):1137-1147. doi: 10.1182/blood.2020009652. Blood. 2021. PMID: 33951732 Free PMC article. Clinical Trial.
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. Laszlo GS, et al. Among authors: wang yc. Clin Cancer Res. 2015 Jul 15;21(14):3187-95. doi: 10.1158/1078-0432.CCR-14-2684. Epub 2015 Mar 30. Clin Cancer Res. 2015. PMID: 25825478 Free PMC article.
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. Laszlo GS, et al. Among authors: wang yc. J Hematol Oncol. 2015 Oct 20;8:115. doi: 10.1186/s13045-015-0215-4. J Hematol Oncol. 2015. PMID: 26487643 Free PMC article. Clinical Trial.
CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
Maxson JE, Ries RE, Wang YC, Gerbing RB, Kolb EA, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y, Zong Z, Mungall AJ, Moore R, Long W, Gesuwan P, Davidsen TM, Hermida LC, Hughes SB, Farrar JE, Radich JP, Smith MA, Gerhard DS, Gamis AS, Alonzo TA, Meshinchi S. Maxson JE, et al. Among authors: wang yc. Blood. 2016 Jun 16;127(24):3094-8. doi: 10.1182/blood-2016-04-709899. Epub 2016 May 3. Blood. 2016. PMID: 27143256 Free PMC article.
miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, Meshinchi S. Ramamurthy R, et al. Among authors: wang yc. Pediatr Blood Cancer. 2016 Dec;63(12):2096-2103. doi: 10.1002/pbc.26157. Epub 2016 Aug 11. Pediatr Blood Cancer. 2016. PMID: 27511899 Free PMC article.
Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. Laszlo GS, et al. Among authors: wang yc. J Hematol Oncol. 2016 Nov 30;9(1):133. doi: 10.1186/s13045-016-0364-0. J Hematol Oncol. 2016. PMID: 27903291 Free PMC article. No abstract available.
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS. Taub JW, et al. Among authors: wang yc. Blood. 2017 Jun 22;129(25):3304-3313. doi: 10.1182/blood-2017-01-764324. Epub 2017 Apr 7. Blood. 2017. PMID: 28389462 Free PMC article. Clinical Trial.
Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Wang YC, Gerbing RB, Sung L, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Vujkovic M, et al. Among authors: wang yc. Blood. 2017 Jun 8;129(23):3051-3058. doi: 10.1182/blood-2017-03-772384. Epub 2017 Apr 14. Blood. 2017. PMID: 28411282 Free PMC article. Clinical Trial.
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. Lamba JK, et al. Among authors: wang yc. J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23. J Clin Oncol. 2017. PMID: 28644774 Free PMC article. Clinical Trial.
4,561 results